Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | February 27, 2015 | March 03, 2015 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 27, 2015 · Filed March 03, 2015
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 108,972 |
Reported balance
After 2015-02-27 transaction · row 1
1 source rowRow 1 · 2015-02-27 · Tax withholding · Disposed 11,530 · Balance 108,972 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 18,963 |
Reported balance
Holding disclosure · report date 2015-02-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 18,963 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2015. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy self for son | 171 |
Reported balance
Holding disclosure · report date 2015-02-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 171 F2: The reporting person disclaims beneficial ownership of all securities held by his son. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2015.
F2: The reporting person disclaims beneficial ownership of all securities held by his son.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 13,270 | $0.00 Strike: $53.19 | $0.00 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · derivative · entry 14 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 13,270 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 23,000 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · derivative · entry 13 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 23,000 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 63,800 | $0.00 Strike: $46.34 | $0.00 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · derivative · entry 12 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 63,800 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 130,944 | $65.50 | $8,576,832.00 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · nonDerivative · entry 10 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,212 Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,247 | $65.40 | $408,553.80 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · nonDerivative · entry 9 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,156 Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 7,156 | $51.21 | $366,458.76 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · nonDerivative · entry 8 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,823 | $55.57 | $101,304.11 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · nonDerivative · entry 7 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 12,835 | $58.71 | $753,542.85 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · nonDerivative · entry 6 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 13,439 | $54.30 | $729,737.70 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · nonDerivative · entry 5 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 4,935 | $53.12 | $262,147.20 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · nonDerivative · entry 4 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 13,270 | $53.19 | $705,831.30 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,000 | $44.16 | $1,015,680.00 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2012 Filed Sep 5, 2012 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 63,800 | $46.34 | $2,956,492.00 |
DisclosureSEC source: 0001179110-12-013703 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2012 Filed Mar 21, 2012 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001179110-12-005521 · edgar.xml · derivative · entry 4 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common shares · 30,000 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| March 19, 2012 Filed Mar 21, 2012 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 30,000 | $60.00 | $1,800,000.00 |
DisclosureSEC source: 0001179110-12-005521 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,145 Read SEC document |
| March 19, 2012 Filed Mar 21, 2012 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 30,000 | $44.16 | $1,324,800.00 |
DisclosureSEC source: 0001179110-12-005521 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2012 Filed Mar 14, 2012 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001179110-12-005044 · edgar.xml · derivative · entry 5 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common shares · 30,000 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| March 12, 2012 Filed Mar 14, 2012 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $58.16 | $110,505.90 |
DisclosureSEC source: 0001179110-12-005044 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,145 Read SEC document |
| March 12, 2012 Filed Mar 14, 2012 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 28,100 | $58.16 | $1,634,296.00 |
DisclosureSEC source: 0001179110-12-005044 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,045 Read SEC document |
| March 12, 2012 Filed Mar 14, 2012 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 30,000 | $44.16 | $1,324,800.00 |
DisclosureSEC source: 0001179110-12-005044 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,446 | $56.73 | $82,024.35 |
DisclosureSEC source: 0001179110-12-004068 · edgar.xml · nonDerivative · entry 6 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,145 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,441 | $56.72 | $422,053.52 |
DisclosureSEC source: 0001179110-12-004068 · edgar.xml · nonDerivative · entry 5 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,591 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $56.72 | $11,344.14 |
DisclosureSEC source: 0001179110-12-004068 · edgar.xml · nonDerivative · entry 4 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,032 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $56.72 | $5,672.02 |
DisclosureSEC source: 0001179110-12-004068 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,232 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,700 | $56.72 | $436,751.70 |
DisclosureSEC source: 0001179110-12-004068 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,332 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,579 | $57.04 | $603,426.16 |
DisclosureSEC source: 0001179110-12-004068 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,032 Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003258 · edgar.xml · derivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common shares · 55,000 shares Expires 2022-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 02/17/2013, 18,333 on 02/17/2014, and 18,333 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 30,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003258 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,611 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| December 02, 2011 Filed Dec 7, 2011 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 53,201 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-11-016153 · edgar.xml · derivative · entry 7 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 53,201 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 02, 2011 Filed Dec 7, 2011 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4 | $54.64 | $218.54 |
DisclosureSEC source: 0001179110-11-016153 · edgar.xml · nonDerivative · entry 4 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,111 Read SEC document |
| December 02, 2011 Filed Dec 7, 2011 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 53,197 | $54.63 | $2,906,152.11 |
DisclosureSEC source: 0001179110-11-016153 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,115 Read SEC document |
| December 02, 2011 Filed Dec 7, 2011 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 53,201 | $53.63 | $2,852,903.63 |
DisclosureSEC source: 0001179110-11-016153 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2011 Filed Dec 7, 2011 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 12,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-016153 · edgar.xml · nonDerivative · entry 6 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Anne Marie Landgraf Living Trust Disclosed balance after: 0 F2 · balance_after: Shares were formerly held in the Anne Marie Landgraf Living Trust. The reporting person and his spouse are co-trustees of the trust. The trust is revocable by his spouse. Read SEC document |
| November 21, 2011 Filed Dec 7, 2011 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 609 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-016153 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,111 Read SEC document |
| June 29, 2011 Filed Jul 1, 2011 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 12,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-010402 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Anne Marie Landgraf Living Trust Disclosed balance after: 12,954 F3 · balance_after: Held in the Anne Marie Landgraf Living Trust. The reporting person and his spouse are co-trustees of the trust. The trust is revocable by his spouse. Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $48.03 | $9,606.10 |
DisclosureSEC source: 0001179110-11-003912 · edgar.xml · nonDerivative · entry 5 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,720 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,492 | $48.03 | $311,810.76 |
DisclosureSEC source: 0001179110-11-003912 · edgar.xml · nonDerivative · entry 4 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,920 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,200 | $48.03 | $345,823.20 |
DisclosureSEC source: 0001179110-11-003912 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,412 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $48.03 | $4,803.07 |
DisclosureSEC source: 0001179110-11-003912 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,612 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,175 | $47.64 | $389,457.00 |
DisclosureSEC source: 0001179110-11-003912 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,712 Read SEC document |
| February 18, 2011 Filed Feb 23, 2011 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 50,100 | $0.00 Strike: $46.60 | $0.00 |
DisclosureSEC source: 0001179110-11-003283 · edgar.xml · derivative · entry 4 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,100 Underlying: Common shares · 50,100 shares Expires 2021-02-17 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,700 on 02/18/2012, 16,700 on 02/18/2013, and 16,700 on 02/18/2014. Read SEC document |
| February 18, 2011 Filed Feb 23, 2011 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 35,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-003283 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,887 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| December 02, 2010 Filed Dec 15, 2010 22:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-017578 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By self for son Disclosed balance after: 2,007 F2 · balance_after: Includes shares acquired under the Abbott Laboratories Dividend Re-investment and Stock Purchase Plan in transactions exempt from Section 16 under Rule 16(a)-11. F3 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his son. Read SEC document |
| December 02, 2010 Filed Dec 15, 2010 22:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-017578 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,287 Read SEC document |
| October 29, 2010 Filed Nov 2, 2010 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,640 | $0.00 Strike: $49.19 | $0.00 |
DisclosureSEC source: 0001179110-10-015481 · edgar.xml · derivative · entry 5 Landgraf John C · CIK 0001298968 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 10,640 shares Expires 2010-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 29, 2010 Filed Nov 2, 2010 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,322 | $51.75 | $534,163.50 |
DisclosureSEC source: 0001179110-10-015481 · edgar.xml · nonDerivative · entry 2 Landgraf John C · CIK 0001298968 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,087 Read SEC document |
| October 29, 2010 Filed Nov 2, 2010 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,640 | $49.19 | $523,423.10 |
DisclosureSEC source: 0001179110-10-015481 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2010 Filed Oct 1, 2010 21:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 555 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-014489 · edgar.xml · nonDerivative · entry 1 Landgraf John C · CIK 0001298968 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,769 Read SEC document |
| June 28, 2010 Filed Jul 23, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 39,651 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-011863 · edgar.xml · nonDerivative · entry 5 Landgraf John C · CIK 0001298968 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Anne Marie Landgraf Living Trust Disclosed balance after: 0 Read SEC document |
| June 16, 2010 Filed Jul 23, 2010 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 9,651 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-011863 · edgar.xml · nonDerivative · entry 3 Landgraf John C · CIK 0001298968 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Anne Marie Landgraf Living Trust Disclosed balance after: 39,651 F2 · balance_after: Held in the Anne Marie Landgraf Living Trust. The reporting person and his spouse are co-trustees of the trust. The trust is revocable by his spouse. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.